| Outcome Measures: |
Primary: Change in 6-minute walking distance (6MWD), Difference in distance walked during 6-minute walking test (6MWT) between 24 weeks after baseline and at baseline, 24 weeks | Secondary: Change in left ventricular mass index (LVMI), Difference in LVMI assessed by echocardiography between 24 weeks after baseline and at baseline, 24 weeks|Change in left atrial volume index (LAVI), Difference in LAVI assessed by echocardiography between 24 weeks after baseline and at baseline, 24 weeks|Change in left atrial stiffness, Difference in left atrial stiffness assessed as a ratio of mitral E/e' ratio to left atrial strain s between 24 weeks after baseline and at baseline, 24 weeks|Change estimated pulmonary artery systolic pressure (PASP), Difference in PASP assessed by echocardiography both at rest and during diastolic stress test (DST) between 24 weeks after baseline and at baseline, 24 weeks|Change in average e' velocity, Difference in average e' velocity assessed by echocardiography both at rest and during diastolic stress test (DST) between 24 weeks after baseline and at baseline, 24 weeks|Change in average E/e' ratio, Difference in average E/e' ratio assessed by echocardiography both at rest and during diastolic stress between 24 weeks after baseline and at baseline, 24 weeks|Change in N-terminal pro b-type natriuretic peptide (NT-proBNP), Difference in NT-proBNP plasma levels between 24 weeks after baseline and at baseline, 24 weeks|Change in Cyclic guanosine monophosphate (cGMP), Difference in cGMP plasma levels between 24 weeks after baseline and at baseline, 24 weeks|Change in Endothelin 1 (ET-1), Difference in ET-1 plasma levels between 24 weeks after baseline and at baseline, 24 weeks|Change in Growth/differentiation factor 15 (GDF-15), Difference in GDF-15 plasma levels between 24 weeks after baseline and at baseline, 24 weeks|Change in ST2, Difference in ST2 plasma levels between 24 weeks after baseline and at baseline, 24 weeks|Change in Galectin-3, Difference in Galectin-3 plasma levels between 24 weeks after baseline and at baseline, 24 weeks|Change in carboxyterminal propeptide of type I collagen (PICP), Difference in PICP plasma levels between 24 weeks after baseline and at baseline, 24 weeks|Change in Human Pentraxin 3 (PTX3), Difference in PTX3 plasma levels between 24 weeks after baseline and at baseline, 24 weeks|Change in high-sensitivity C-reactive protein (hsCRP), Difference in hsCRP plasma levels between 24 weeks after baseline and at baseline, 24 weeks|Change in Interleukin-6 (IL-6), Difference in IL-6 plasma levels between 24 weeks after baseline and at baseline, 24 weeks|Change of New York Heart Association (NYHA) functional classification, Difference in NYHA class between 24 weeks after baseline and at baseline, 24 weeks|Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) score, Difference in MLHFQ score between 24 weeks after baseline and at baseline. The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. After receiving brief standardized instructions, the patient marks a 0 (zero) to 5 scale to indicate how much each itemized adverse of heart failure has prevented the patient from living as he or she wanted to live during the past 4 weeks. The questionnaire is simply scored by summation of all 21 responses. Score ranges from 0 (best quality of life) to 105 (worst quality of life)., 24 weeks
|
